Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Zai Lab Q3 2026 Results: Net Loss of $46.1M, Loss Widens

Zai Lab Limited filed its Q3 2026 report as a large accelerated filer, reporting 1,124,448,350 ordinary shares outstanding as of October 31, 2026. The filing outlines significant risk factors related to its operations in mainland China, including regulatory uncertainties, manufacturing compliance, and geopolitical tensions.

Watch the Zai Lab Ltd earnings callFull call on the ALFA USA YouTube channel
Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue108.2116.1
Profit before tax-48.0-36.0
Net income-46.1-36.0
EPS (diluted, $ a share)$-0.04$-0.03

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year-6.8%
Operating margin-58.2%
Source

10-Q filed with the SEC, NASDAQ: ZLAB. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Zai Lab Ltd: key numbers

Share price
$23.47Close, Nov 16
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Zai Lab Ltd

All →
5:48 PM ET Form 4
Insider Buying

Zai Lab Director Richard Gaynor Buys $33.4K of Stock

Richard Gaynor, Director, bought 1,228 shares of Zai Lab Ltd at $27.19 a share, worth $33.4K in total on Nov 10, 2026. Shares held after the trade: 81,965 (+1.5%).

Value
$33.4K
Shares
1,228
Price
$27.19
Role
Director
Holding change
+1.5%
Trade date
Nov 10, 2026
6:37 AM ET 8-K
Financial Results

Zai Lab Financial Results

Zai Lab reported third quarter 2026 total revenues of $108.2 million, representing a 2% sequential increase in net product revenue. The company highlighted positive clinical data for its internally developed ADC, zocilurtatug pelitecan (zoci), in small cell lung cancer and expects 2027 to be a pivotal year with its first potential U.S. BLA submission.

Term
Q3 2026

“We are approaching a defining period for Zai Lab, as we advance toward bringing our first internally developed innovative medicines to patients globally. The strong first-line combination data for zocilurtatug pelitecan (zoci) presented at ESMO strengthen our confidence in its potential to become an ADC backbone of choice in small cell lung cancer.”

Dr. Samantha Du, Founder, Chairperson and Chief Executive Officer of Zai Lab

“This profile supports taking a standard chemotherapy-free regimen into a global Phase 3 study and gives us a strong foundation to build on with T-cell engager combinations. Our registrational programs in SCLC and neuroendocrine carcinomas are advancing toward readouts that could support our first U.S. BLA submission in 2027.”

Rafael G. Amado, M.D., President, Head of Global Research and Development at Zai Lab
6:07 AM ET 8-K
Capital Raise

Zai Lab Capital Raise of $250M

Zai Lab Limited entered into a securities purchase agreement with accredited investors for a private placement (PIPE) of 11,340,000 American depositary shares (ADSs). The company expects to receive gross proceeds of approximately $250 million to fund pipeline development and general corporate purposes. The ADSs are priced at $22.04 each, and the company has agreed to file a registration statement for the resale of these securities.

Value
$250M

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.